2025-522084-15-00招募中3 期
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 14
- 主要终点
- progression free survival (PFS) - Overall survival (OS)
研究概览
简要总结
Phase II: Progression free survival (PFS) Phase III: Overall survival (OS)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Histologically or cytologically confirmed metastatic NSCLC. Patients with stage III disease are eligible if they are not candidates for surgical resection or definitive chemoradiation. Patients with Large Cell Neuroendocrine Carcinoma (LCNEC) are not eligible.
- •Confirmed EGFR and ALK mutation negative disease based on testing consistent with local guidelines.
- •Patients must have a PD-L1 test result from a certified laboratory indicating PD-L1 expression Tumour Proportion Score (TPS) ≥ 50%. Patients with lower PD-L1 TPS scores treated with single agent pembrolizumab consistent with local guidelines and regulatory approvals may be eligible following discussion with CCTG.
- •Patients must have received at least and not more than 2 cycles of the 200 mg or 2 mg/kg IV Q3W dose/schedule of pembrolizumab, or at least and not more than 1 cycle of 400 mg or 4 mg/kg IV Q6W dose/schedule of pembrolizumab as first line systemic immunotherapy for advanced metastatic NSCLC at the time of screening.
- •Prior chemotherapy or immunotherapy for non-metastatic disease (e.g. adjuvant and/or neoadjuvant therapy) is allowed if at least 6 months have elapsed between the completion of prior therapy and start of pembrolizumab as first line treatment for metastatic disease. Local therapy, e.g. palliative extra-cranial radiation, is allowed as long as a period of 2 weeks has passed since completion and screening as ctDNA level may be altered by radiotherapy. Please contact CCTG if a patient has received palliative extra-cranial radiation and a 2 weeks delay is not possible. Eligibility will be considered on a case by case basis. There is no requirement for delay for patients who have received brain radiation. Patients must have recovered to ≤ grade 1 from all reversible toxicity related to prior systemic or radiation therapy. Previous major surgery is permitted provided that surgery occurred at least 14 days prior to screening of ctDNA and 28 days prior to patient enrollment and that wound healing has occurred.
- •Eligible and suitable to receive continued treatment with pembrolizumab OR the addition of chemotherapy to pembrolizumab. Patients should be clinically stable without evidence of clinical progression or symptomatic deterioration that requires change in cancer treatment.
- •Must be ≥ 18 years of age.
- •ECOG performance status 0-
- •Clinically and/or radiologically documented and evaluable disease. Measurable disease as defined by RECIST is not required.
- •Imaging investigations including CT of the chest, abdomen and pelvis and MRI/CT of the brain (if known brain metastases) or other scans as necessary to document all sites of disease must be done within 14 days prior to randomization to ensure patients do not have clinical progression requiring change in systemic treatment.
- •Patients must have RECIST non-PD or clinically stable PD documented prior to enrollment that can continue on IO therapy if randomized to that arm.
- •Detectable ctDNA on screening is required for subsequent enrollment and randomization. For other criteria see the protocol
排除标准
- •Patients with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the protocol treatment regimens are eligible for this trial.
- •Patients with symptomatic central nervous system (CNS) metastases and/or CNS metastases requiring immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone equivalents). Patients with known central nervous system metastases who are asymptomatic and on a stable dose of corticosteroids ≤ 10 mg/day prednisone equivalents are eligible.
- •Patients who are not suitable candidates for treatment with pembrolizumab as a single agent or in combination with standard platinum combination chemotherapy according to the current guidance/indications described in the Product Monograph (Canada) or Drug Label (U.S.) and practice guidelines including but not limited to patients with active infection, autoimmune disease, conditions that require systemic immunosuppressive therapy (such as transplant patients) and patients with a history of severe immune-mediated adverse reactions, or known hypersensitivity to pembrolizumab or its components. Patients with pre-existing conditions such as colitis, hepatic impairment, respiratory or endocrine disorders (such as hypo or hyperthyroidism or diabetes mellitus), can be considered for enrollment to this study provided pembrolizumab is administered with caution and patients are closely monitored. Patients should not have contraindications to platinum combination chemotherapy.
- •History of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements.
- •Concurrent treatment with other anti-cancer therapy or other investigational anti-cancer agents.
- •Pregnant or lactating women.
结局指标
主要结局
progression free survival (PFS) - Overall survival (OS)
progression free survival (PFS) - Overall survival (OS)
次要结局
- Feasibility
研究者
Maria Carmela Piccirillo
Scientific
IRCCS Istituto Nazionale Tumori Fondazione Pascale
研究点 (14)
Loading locations...
相似试验
招募中
2 期
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST CANCER (THE CADILLAC STUDY)2024-520027-88-00Medica Scientia Innovation Research S.L., Medica Scientia Innovation Research S.L.27
招募中
2 期
Prospective study in patients with colon or rectum cancer with liver metastasis of the efficacy and toxicity of standard therapy (chemotherapy + targeted therapy) combined with immunotherapy and internal radiotherapy targeting the liver2024-517204-11-00Fondation Franc.Cancerologie Digestive52
招募中
3 期
Extension Study for Participants in Studies That Include Pembrolizumab2022-501254-10-00Merck Sharp & Dohme LLC1,133
招募中
1 期
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesChronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisMultiple SclerosisNCT07304154Kite, A Gilead Company52
招募中
4 期
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed on platinum-based chemotherapy2022-501606-35-01Immunogen Biopharma (Ireland) Limited, Immunogen Inc.110